Market Research Blog

Macadamia’s beneficial nutritional profile has been captivating consumer interest in recent years. With fostering consumption of dried fruits and nuts, the market for macadamia nuts also holds an optimistic growth outlook for the next few years. As indicated by a recent research report released by Future Market Insights, the global market for macadamia is foreseen to expand at a CAGR of 7.5% over a 10-year projection period, 2022-2032. However, high price point remains a longstanding barrier to widespread consumption, coupled with availability of a range of cheaper tree nut product alternatives.

Of the total global macadamia consumption, around 35% is being registered by the food processing industry that uses the nut as an innovative ingredient in ice creams and snacks. The research also highlights a slew of opportunities that exist in the food processing segment, which are expected to provide an impetus to market growth. Product innovation and boosting sales of processed food segments such as snacks and ice-cream have been identified to be among the most prominent factors pushing the performance of macadamia market, worldwide. The US$ 2.23 billion macadamia market is likely to witness a prominent drive by growing consumer preference for vegan food products, as depicted in Future Market Insights’ (FMI) recently released report, titled ‘Macadamia Market’: Global Industry Analysis 2017-2021 and Opportunity Assessment 2022-2032.’

Spike in Consumption Rate to be Witnessed by Developing Economies in MEA & APEJ

North America has been the top producer as well as consumer of tree nut, followed by MEA and APEJ. While North America is presumed to remain one of the key markets for macadamia, MEA is believed to remain a dominant regional market – registering the highest consumption volume as well as value throughout the projection period. This growth is highly attributed to incredible opportunities for macadamia nut procedures in South African region. The global macadamia market is now a buyer negotiated space and with growing demand for size and quality, South Africa is believed to be a key market, eventually pushing the prospects for MEA. The demand and consumption of macadamia nuts in China is growing at a rapid pace, which is strongly influencing the market performance in Asia Pacific.

New Application Areas Debut, Creating Attractive Growth Prospects

Research findings indicate that consumption of nuts has been strongly associated with a relatively lower risk of obesity and metabolic syndrome, which will trigger a proliferating trend of increased consumption of tree nuts, including macadamia. Moreover, the Omega 7 oil content of macadamia nuts is likely to unlock new target end uses such as anti-aging cosmetics. European and Asian economies are expected to raise substantial demand for macadamia-based cosmetic products in near future.

New Product Launches & Impactful Product Promotion to be the Key to Market Expansion

A majority of manufacturers are targeting new markets for expansion, as suggested by the research. While acquisition of prominent regional players is expected to be a key to regional footprint expansion, enhancement of brand portfolio and strengthening of distribution network will also remain among the prominent strategies adopted by leading players in the market. Product promotion and consumer awareness are foreseen to be the top-of-mind priorities for manufacturers.

In addition, companies are also striving to enter key international markets through mergers. Several players are enhancing their production capacity to cater to rapidly growing demand for macadamia products. As key participants in the global macadamia market concentrate more on novel product development and innovative product launches, online (social media) marketing is expected to be on the priority for key manufacturing companies in macadamia market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1304

Key Takeaways: Insights on Market Taxonomy

• Easy availability and affordability enable conventional macadamia to remain a dominant product by nature. However, organic macadamia is likely to encounter with lucrative opportunities over 2022-2032, prominently in European and North American markets.
• Raw and processed macadamia will continue to gain higher traction, as the demand from processed food industry prevails. The next decade will possibly see substantially growing demand for macadamia kernel.
• In-shell nuts are witnessing significant demand from the food and beverages industry in developing regional markets, owing to advancement of processing activities.
• Industrial sector, including food, dairy, bakery, confectionary, and snacks industry, will lead in terms of end use, while growing applications will uplift the residential sector through 2032.
• Indirect sales are expected to be supported by growing macadamia consumption by food and cosmetics industries.

The market has been segmented as below :

By Nature :

• Organic
• Conventional

By Form :

• Raw
• Processed
• Oil

By End Use :

• Residential
• Commercial
• Industrial
• Food Industry
  • Confectionery
  • Bakery
  • Dairy
  • Snacks
  • Others
• Cosmetic and Personal Care

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-1304

By Distribution Channel :

• Direct
• Indirect

The recent past has observed an increased in number of HNWI population in 2018. Globally, HNWI population reached 22.4 million, and their total wealth accounted for US$ 61,275 Bn in 2018. Europe accounted for high growth rate of HNWI population, with almost 5.6 Mn HNWI population. This leads to high purchasing power of individuals. In addition, growing working women population and women’s labor force participation in regions such as Japan, the United Kingdom, and France help increase their purchasing power to buy luxury footwear.

Over 2 million new cases of lung cancer were registered globally by the end of 2018, as reported by the American Cancer Society, Inc. The global lung cancer surgery landscape currently represents a US$ 1 Bn market and will expand at a strong CAGR during the period of projection, 2019 – 2029. A new Future Market Insights (FMI) report states that the use of techniques that are minimally invasive, video assisted, and robot assisted is growing, which is shaping the future of lung cancer surgery market.

Future Market Insights, Dubai: As per ESOMAR-certified consulting firm Future Market Insights (FMI), the global companion animal specialty drugs market registered steady year-on-year (YoY) growth at 5.42% CAGR in 2021.

Increasing pet adoption is a major factor, fuelling the demand for animal nutrition and behavioral products, thereby accelerating sales. With increasing rate of obesity among the pet, demand for anti-obesity drugs have burgeoned over the past few years.

Adoption of canine and feline pets increased during the FQ-20, due to the outbreak of COVID-19 and consequent global shutdown. Adoption of dogs is quite high, especially among the geriatric population. This is expected to drive the demand for antibiotics, skin-care, and nutritional products for pets.

As per FMI, the market is expected to reach a valuation of US$ 36,104.66 Mn in 2021 owing to the increasing demand for anti-obesity drugs across veterinary clinics. Alongside this, prevalence of canine vector-borne diseases due to bacteria and protozoa infection will fuel the demand for parasiticides in the next decade.

To remain ‘ahead’ of your competitors, request for a sample– https://www.futuremarketinsights.com/reports/sample/rep-gb-3984

“The demand for compounded medications and anti-obesity drugs for animals will continue increasing in the coming years. This has encouraged some of the leading companies to focus on research initiatives to launch novel drugs to facilitate improved care for companion animals. This will create impressive growth opportunities in the coming years,” says the FMI analyst.

Key Takeaways from FMI’s Companion Animal Specialty Drugs Market Study

• By product type, parasiticides will dominate the market, accounting for over 32% of global market share.
• In terms of distribution channel, veterinary clinics are expected to lead the segment contributing over 52% of value share by 2031
• In terms of technology type, drying technology is predicted to exceed US$ 89 Bn by end 2031
• The U.S. will emerge as the leading market across North America backed by the high adoption of pet dogs
• Germany and the U.K. are anticipated to lead the Europe’s Companion animal specialty drugs market, owing to the growing obesity rate in dogs
• Increasing cases of neglect and animal cruelty in India will bolster the demand for companion animal specialty drugs through 2021

Competitive Landscape

Zoetis Inc., Merck and Co., Inc., Bayer AG, Eli Lily and Co. and Boehringer Ingelheim GmbH are the key players operating in the companion animal specialty drugs market. among others are some prominent players operating in the Companion animal specialty drugs market.

For instance, in July 2020, Boehringer Ingelheim announced the launch of two new products, NexGard and Broadline, to provide comprehensive parasite treatment for dogs and cats, to expand their product portfolio for the India market.

As per the report, key players are focusing on product introduction and launches to expand their product portfolios. Key player are also involved extensively in strategic acquisition activities which has led to severe competition among companion animal specialty drugs market players.

For example, on August 4,2021, Zoetis, the Parsippany-based animal health company announced the acquisition of a leading Australian-based Jurox’s veterinary medicines, maker of livestock and companion animal medicines.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-3984

What else is in the report?

Future market insights offers a unique perspective and actionable insights on companion animal specialty drugs market in its latest study, presenting historical demand assessment from 2016 – 2020 and projections from 2021-2031 based on product type (antibiotics, anti-inflammatory drugs, parasiticides, heartworm, behavioral products, nutritional products, anti-obesity drugs, skin care products and vaccines), distribution channel (veterinary hospitals, veterinary clinics and pharmacies and drug stores) in seven key regions (North America, Latin America, Eastern Europe, Asia Pacific excluding Japan, Western Europe, Japan and Middle East & Africa)

Companion Animal Specialty Drugs Market by Category

By Product:

• Antibiotics
• Anti-Inflammatory Drugs
• Parasiticides
• Heartworm
• Behavioral Products
• Nutritional Products
• Anti-Obesity Drugs
• Skin Care Products
• Vaccines

By Distribution Channel:

• Modern Trade
• Online Distribution
• Neighborhood Stores
• Other Retail Format

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-3984

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa (MEA)

Adoption of hospital management capacity solutions will grow at 5.1% CAGR through 2027, according to a latest research by Future Market Insights (FMI). Increasing need for enhanced health safety will influence healthcare institutes to adopt IT/HCMS. Furthermore, emphasis on financial and clinical integration will push incorporation of robust IT infrastructures such as PLEXIS.

Adoption of HCMS is also increasing as it enables users to access real-time location services. As healthcare institutes grapple with rising operating costs, HCMS is being looked upon as a next-gen solution that reduces medical and administrative errors. The market will also continue to be influenced by the broader industry-wide push to amalgamate IT with operations.

Moreover, political dynamics have impacted the process of demand and supply through implementation of various healthcare related evolutions and reforms such as ‘The Patient Protection and Affordable Care Act’. The Patient Protection and Affordable Care Act mandates various regulations and requirements regarding storing, capturing and sharing data, which will bring fundamental transformation in various healthcare-related operations. In addition, enhanced technology such as wireless communication and easy internet accessibility, incorporated with various healthcare applications will create new opportunities and enable patients to access related information whenever they need it. Such factors are likely to contribute towards growth of the HCMS market.

However, Future Market Insights identifies that security breaches and vulnerabilities associated with IT will continue to hinder its widespread adoption. Imposition of complicated regulations by governments for enhanced quality and services, along with lack of integration with regards to analytical solutions with platforms such as electronic health record (EHR) can also pose challenges to growth of the HCMS market.

To remain ‘ahead’ of your competitors, request for a sample– https://www.futuremarketinsights.com/reports/sample/rep-EU-3520

By product type, real-time locating system will account for a majority revenue share of the market. This segment accounted for US$ 88.34 Mn in 2016, and is expected to register highest CAGR through 2027. Event-driven solutions segment is expected to exhibit second-highest CAGR of 5.2% over the following decade.

Regional Analysis

U.K., with total revenues to the tune of US$ 50.78 Mn in 2016, is the largest market for hospital capacity management solutions in Europe. It will remain the largest, and the fastest-growing market in Europe, during the forecast period. The HCMS market in Germany is expected to surpass US$ 80 Mn by 2027.

Vendor Insights

Leading players mainly focus on strategies such as expanding their global footprints through collaboration, conferences, product expansions, partnerships and strengthening distribution networks. Demand for applications and systems for new business requirements will intensify partnerships, mergers and acquisitions and consolidations among market players. Vendors are actively entering into partnerships and acquisitions to consolidate their position in the market. Moreover, majority of the stakeholders in healthcare are adopting cloud computing solutions to address security, scalability and availability issues.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-EU-3520

Key players operating in the Europe HCMS market include

• Awarepoint Corporation,
• Allscripts Healthcare Solutions, Inc.,
• Cerner Corporation,
• McKesson Corporation,
• Epic Systems Corporation,
• TeleTracking Technologies, Inc.,
• Central Logic,
• Sonitor Technologies, Inc.,
• STANLEY Healthcare Solutions Limited
• Care Logistics LLC.

Market Taxonomy

By Product Type

• Workflow Management Solutions
• Asset Management Solutions
• Bed Management Solutions
• Quality Patient Care Solutions
• Real Time Locating System (RTLS)
• Event Driven Solutions Online Registration Solutions Attendance Management Tools Event Driven Patient Tracking Others

By Application

• Standalone Solutions
• Integrated Solutions

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-EU-3520

By Country

• U.K.
• France
• Germany
• Italy
• Spain
• Benelux
• Nordic
• Russia
• Poland
• Rest of Europe

Ablation devices are gathering momentum around the world, owing to their proven procedural efficacy, improved safety profiles, and awareness in current asymptomatic procedure-related events. Over the last decade, ablation devices have undergone significant technical improvements. These devices offer the benefits of enhanced patient quality of life, patient safety, and clinician efficiency, and are used as a frontline therapy. Decrement in long-term hospitalization and minimal invasion are critical factors that are expected to propel the growth of the ablation devices market over the coming years. Ablation devices have gained clinical significance on the basis of effective treatment across various medical applications, as well as due to shorter recovery time with affordable minimal invasive procedures. Moreover, rising prevalence of chronic diseases such as cardiovascular diseases and tumors are expected to provide impetus to market growth.

However, the coronavirus (COVID-19) pandemic has put forward a challenging situation for players in the ablation devices market. The pace at which the pandemic is spreading and the resultant humanitarian toll is making it difficult for market players to react accordingly. As the healthcare industry is addressing the pandemic along with patients’ ever-evolving expectations, market players are devising future-ready strategies to brace themselves for the humanitarian and economic concerns ahead.

The global ablation devices market was valued at US$ 2.7 Bn in 2018, and is anticipated to witness a CAGR of 11% during the forecast period (2019–2029).

“Significant morbidity reduction, prompt hospital discharge, minimally-invasive alternatives to traditional surgical treatment, and fewer risks associated with procedures are key factors influencing healthcare service providers to shift to ablation devices”.

To remain ‘ahead’ of your competitors, request for a sample

Key Takeaways of Ablation Devices Market Study

Advanced ablation catheters has emerged as the largest segment by product type, representing 68% of overall revenue of the ablation devices market in 2018. This is attributed to being a viable alternative management strategy and their frequent use in the clinical management of paroxysmal atrial fibrillation. Further, better clinical outcomes through new ablation technologies to treat most arrhythmias and certain types of structural heart disease are responsible for their significant market share.

Hospitals accounted for a leading revenue share of 52%, owing to the availability of ablation devices and skilled personnel for better clinical management of various diseases across several medical domains.

Radiofrequency captured a major value share in the technology segment, attributable to its lesser potential risk and side effects, lesser recovery time, and its effective application on patients suffering from multiple tumors.

By functionality, automated or robotic ablation devices are expected to grow at an impressive rate; these accounted for around one-third of the global ablation devices market in 2018.

Cumulatively, North America and Europe hold a major share of the global ablation devices market, with the former holding a noteworthy share, and is expected to progress at a high CAGR during the forecast period.

Increasing prevalence of chronic diseases, high purchasing power, technology advancements, and government support for quality healthcare are contributing to the hegemony of North America in the ablation devices market, in terms of value.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-11254

Ablation Devices Manufacturers to Focus on New Product Launches

Continuous upgradation and product launches in the ablation devices market are spurring intense competition among market players. Several companies are focusing on new product approvals for ablation devices. For example, in February 2017, Hologic, Inc. launched a next-generation NovaSure ADVANCED global endometrial ablation (GEA) system in the U.S. This system has been approved by the Food and Drug Administration (FDA). Regional and local players are also implementing these differentiating strategies to sustain their competitiveness.

ABLATION DEVICES MARKET TAXONOMY

The global ablation devices is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Product Type

• Bipolar Energy Ablation Devices
• Cryotherapy Ablation Devices
• Hydrothermal Ablation (HTA) Devices
• Thermal Balloon Ablation Devices
• Advanced Ablation Catheters
• Cryoablation Catheters
• Irrigated tip RF Ablation Catheters
• Laser Ablation Catheters
• Standard Ablation Catheters
• Conventional Radiofrequency Ablation Catheters
• MRI Guided Neurosurgical Ablation
• MRI Guided Laser Therapy Systems
• MRI Guided RF Ablation Systems
• MRI Guided Focused Ultrasound Systems
• Accessories

Technology

• Laser
• Radiofrequency
• Microwave
• Ultrasound
• Others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-11254

Application

• Cardiovascular
• Cancer
• Urological
• Ophthalmic
• Others

Functional

• Automated Robotics
• Conventional

End User

• Hospitals
• Ambulatory Surgical Centers
• Clinics

Regions

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• MEA

ESOMAR-certified Future Market Insights (FMI) has recently published an exhaustive yet unbiased analysis of the global Gaucher and Pompe disease ERT market providing insights on key growth trends through 2030.

As the global burden of genetic disorders such as Gaucher disease, Fabry disease, Pompe disease and other abnormalities rise, healthcare providers are scrambling to develop potential therapeutic approaches to offset their impacts.

According to the National Gaucher Foundation, one in every 450 people belonging to the Ashkenazi Jewish community suffer from Type-1 Gaucher disease, the most prevalent form, thereby opening up credible growth prospects for the future.

Key Takeaways

• Gaucher and Pompe Disease ERT market to expand at 5.6% value CAGR through 2020
• Type-1 non-neuronopathic Gaucher disease to remain key treatment area, accounting for over 90% revenue by 2020-end
• Parenteral ERT administration to be most frequent, attributed to high demand for precision-based medicine
• Online pharmacies gaining credible impetus, expanding at over 7% CAGR through 2030
• Europe to retain lucrativeness, North America to be the 2nd largest market by 2030

“Increasing regulatory approvals by government authorities is paving way for the entry of prominent enzyme replacement therapy providers, thus generating immense revenue prospects across promising markets,” concludes the FMI analyst.

To remain ‘ahead’ of your competitors, request for a sample 

COVID-19 Impact Analysis

As healthcare organization reorient their resources to fight the coronavirus pandemic, the market for Gaucher & Pompe Disease ERT experienced a substantial blip in the initial months, with treatment sessions declining significantly across several countries.

For instance, until July 2020, Spain recorded a 25% decline in enzyme replacement therapy sessions amongst people suffering from Type-1 and Type-3 Gaucher Disease respectively. This largely occurred as a consequence of rescheduling treatments at a later date.

In the United States, hospital visits to avail ERT have registered considerable decline for avoiding exposure to COVID-19 patients. As a result, patient self-administration at home have burgeoned. Furthermore, the pandemic has provided an opportunity to undertake research on lysosomal dysfunction and disease pathogenesis which would enhance clinical care.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-12771

Competitive Landscape

Prominent players operating in the Gaucher & Pompe Disease ERT landscape include Shire PLC, Ultragenyx Pharmaceuticals Inc., Sigma-Tau Pharmaceuticals Inc., Pfizer Inc., Alexion Pharmaceuticals Inc., Sanofi SA, Merck KGaA, Tadeka Pharmaceuticals, AbbVie Inc. and BioMarin Pharmaceutical Inc. to name a few.

Manufacturers rely on introduction of novel technologies to advance effective ERTs for numerous genetic conditions. For instance, in October 2018, the U.S Food & Drug Administration approved Sigma-Tau Pharmaceuticals’ (Lediant Biosciences) RevcoviTM injection for treating adenosine deaminase severe combined immune deficiency (ADA-SCID).

Likewise, Sanofi SA markets the Cerezyme® ERT ­injections through its Genzyme subsidiary, which offers a long term efficacy to elderly and pediatric patients suffering from Type-1 Gaucher Disease, and is the only known long-term cure for the condition.

More Insights on FMI’s Gaucher and Pompe Disease ERT Market Report

Future Market Insights, in its new report, offers an unbiased analysis of the global Gaucher and Pompe Disease ERT market, analyzing historical demand from 2015-2019 and forecast statistics for 2020-2030. The study reveals growth projections on the Gaucher and Pompe Disease ERT Market on the basis of therapeutic condition (Gaucher disease and Pompe disease), route of administration (oral and parenteral) and distribution channel (hospital pharmacies, specialty treatment pharmacies, retail pharmacies and online pharmacies) across seven prominent regions.

Key Segments

Therapeutic condition

• Gaucher Disease
• Type 1 (non-neuropathic)
• Type 2 (acute infantile neuronopathic)
• Type 3 Gaucher disease (chronic neuronopathic)
• Perinatal lethal Gaucher disease
• Cardiovascular Gaucher disease
• Pompe Disease
• Classic infantile-onset
• Non-classic infantile-onset
• Late-onset

Route of Administration

• Oral
• Parenteral

Distribution Channel

• Hospital Pharmacies
• Specialty Treatment Pharmacies
• Retail Pharmacies
• Online Pharmacies

For in-depth competitive analysis Buy Now – https://www.futuremarketinsights.com/checkout/12771

Region

• North America (U.S & Canada)
• Latin America (Brazil, Mexico, Argentina & Rest of LATAM)
• Europe (U.K, Germany, France, Spain, Italy, Russia & Rest of Europe)
• East Asia (China, Japan & South Korea)
• South Asia (India, Thailand, Indonesia, Malaysia & Rest of South Asia)
• Oceania (Australia & New Zealand)
• Middle East & Africa (GCC, South Africa, Turkey & Rest of MEA)

The hematology diagnostics market has witnessed the advent of a wide range of hematology testing solutions that combine the attributes of strainer, slider maker, and cell counter. Integrated solutions have been gaining ground in the hematology diagnostics market, as growing work load has prompted pathologists to adopt methods with precision and accuracy for improved results.

According to a recent study of Future Market Insights (FMI), the hematology diagnostics market recorded a valuation of approximately US$ 3,500 Mn in 2017. Growing popularity of modern day analyzers that offer five to seven parts white cell differential analysis, along with additional information on cell population data (CPD), large unstained cell population, and granularity index, will continue to drive growth of the hematology diagnostics market.

The study opines that the hematology diagnostics market will continue to remain a consolidated landscape, with few established players collectively accounting for a larger share of the market. Robust portfolio, and stronger distribution footprint of these leading players, including F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Abbott Laboratories, and Sysmex Corporation, will continue to uphold their lead in the hematology diagnostics market in the upcoming years.

“To remain ‘ahead’ of your competitors, request for a sample” – https://www.futuremarketinsights.com/reports/sample/rep-gb-9046

Key players in the hematology diagnostics market are focusing on strategic partnerships with vendors having innovative technologies, to gain a greater share with more diverse portfolios. Other leading players profiled in the report on the hematology diagnostics market include

HORIBA, Ltd., HemoCue AB, Mindray Medical International Limited, Danaher (Beckman Coulter, Inc.), Bio-Rad Laboratories, Inc., and Siemens Healthineers.

Emphasis on Effective Hematology Diagnostics to Surge in Line with Prevalence of Blood Cancer

There has been a marked rise in the prevalence of blood disorders, and the pervasiveness of these ailments will continue to surge in the foreseeable future, according to the report. This has further driven the essentiality of hematology diagnostics with greater efficacy, thereby complementing new product developments and technological advancements in the hematology diagnostics market worldwide.

Recent studies from associated regulatory authorities estimated that, in the US alone, number of individuals affected with blood-related disorders reached nearly 173,000 in 2017. This has further led the healthcare institutes and governments to take up initiatives for increasing awareness of these disorders and the availability of related management & treatment procedures, which in turn has led the demand and adoption of hematology diagnostics in the recent past.

Point-of-care testing has also witnessed a notable rise in demand, with technological advancements leading to results with higher accuracy and convenience. Easy availability of myriad test methods for hematology diagnostics has also been a key factor driving growth of the market. The study estimates that the hematology diagnostics market

Gains from Hematology Diagnostics Market in Developed Markets to Remain Higher

The study anticipated Europe and North America to remain the most lucrative markets for the hematology diagnostics market. Relatively greater prevalence of blood-related disorders, higher awareness about the existing screening techniques for blood disorders, and rising expenditure on health & wellness by consumers, allude greater gains from the hematology diagnostics market in Europe and North America.

Sensing varied requirements of the healthcare settings and the distinctions in the blood ailments, key players in the hematology diagnostics market have introduced a wide range of hematology instruments, According to the study, hematology analyzers currently accounts for the largest share in the hematology diagnostics market.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-9046

This FMI report also offers an accurate forecast of the hematology diagnostics market for the period between 2018 and 2026. The hematology diagnostics market is envisaged to record a CAGR of over 5% through 2026.

Key Segment

On the basis of product type

hematology consumables

hematology instruments

On the basis of end-user

diagnostic laboratories

academic institutes

hospitals & clinics

others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-9046

On the basis of region

North America

Asia Pacific

Latin America

Europe

MEA (Middle East & Africa)

Rising prevalence of cancer is likely to fuel the demand for cancer diagnostics. A study by Future Market Insights (FMI) projects the cancer diagnostics market to surpass US$ 47.62 Bn in 2021. According to the World Health Organization (WHO), cancer is the second -leading cause of death globally, accounting for over 9.9 million deaths in 2020. Rising cases of cancer have been fuelling the demand for advanced diagnostics.

Future Market Insights’ recent report on the reprocessed medical devices market in Asia-Pacific region projects that in 2017 and beyond, Japan, China and Southeast Asia will collectively account for more than 60% share of overall market revenues. The report estimates that reprocessed medical devices market in Asia-Pacific is presently valued at US$ 236.9 Mn. In a ten-year forecast period, the market is being projected to expand at 15.7% CAGR and bring in a little over US$ 1 Bn by the end of 2027.